^
BIOMARKER:

CD44 expression

i
Other names: CD44, CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1
Related biomarkers:
Phase 2
Mayo Clinic
Active, not recruiting
Last update posted :
06/18/2021
Initiation :
07/06/2017
Primary completion :
12/15/2021
Completion :
12/15/2021
HER-2 • ER • CD24 • CD44 • SOX2
|
HER-2 amplification • ER positive • HER-2 negative • HER-2 expression • ER negative • CD44 expression
|
fulvestrant • alisertib (MLN8237)
Phase 1/2
AGC Biologics S.p.A.
Recruiting
Last update posted :
02/24/2021
Initiation :
08/27/2019
Primary completion :
06/28/2023
Completion :
06/28/2023
FLT3 • CD44
|
FLT3 mutation • CD44 expression
|
fludarabine IV • CAR-CD44v6 • cyclophosphamide intravenous
Phase 2
Vanderbilt-Ingram Cancer Center
Active, not recruiting
Last update posted :
01/22/2021
Initiation :
06/16/2015
Primary completion :
01/01/2021
Completion :
08/01/2021
CD44
|
CD44 expression
Phase 1
SOLTI Breast Cancer Research Group
Recruiting
Last update posted :
01/06/2021
Initiation :
10/22/2020
Primary completion :
04/30/2021
Completion :
10/28/2021
HER-2 • ER • CD24 • CD44 • ALDH1A1
|
ER positive • HER-2 negative • CD44 expression
|
Apristor (onapristone XR)
Phase 1/2
Shenzhen Geno-Immune Medical Institute
Recruiting
Last update posted :
06/12/2020
Initiation :
06/01/2020
Primary completion :
05/31/2023
Completion :
12/31/2023
HER-2 • CD44
|
HER-2 expression • CD44 expression
|
4SCAR-T
Phase 3
Indonesia University
Completed
Last update posted :
12/09/2019
Initiation :
07/04/2017
Primary completion :
07/30/2018
Completion :
12/18/2018
HIF1A • CD133 • CD44
|
HIF1A expression • CD133 expression • CD44 expression
|
cisplatin
Phase N/A
Baylor Research Institute
Terminated
Last update posted :
03/27/2019
Initiation :
09/01/2017
Primary completion :
03/25/2019
Completion :
03/25/2019
IDH2 • AKT1 • CD133 • CD44 • ABCC3 • ABCC4
|
CD133 expression • CD44 expression
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
09/11/2017
Initiation :
07/01/2012
Primary completion :
12/01/2013
Completion :
08/15/2016
EGFR • HER-2 • CD44 • ALDH1A1
|
HER-2 amplification • EGFR mutation • HER-2 overexpression • CD44 expression
|
Herceptin (trastuzumab) • paclitaxel • lapatinib
Phase 1
Hoffmann-La Roche
Completed
Last update posted :
11/02/2016
Initiation :
06/01/2011
Primary completion :
03/01/2014
Completion :
03/01/2014
CD44
|
CD44 expression
Phase 1/2
University Health Network, Toronto
Completed
Last update posted :
07/10/2015
Initiation :
05/01/2010
Primary completion :
02/01/2012
Completion :
02/01/2014
EGFR • CD44
|
EGFR mutation • EGFR amplification • EGFR expression • CD44 expression
|
Vizimpro (dacomitinib)
Phase 1
MolMed S.p.A.`MOLMED S.P.A
Ongoing
FLT3 • CD44
|
FLT3 mutation • CD44 expression
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our